2017-10-18 11:00:08

Enzymatica AB: Complete article from COLDPREV I study published - strengthens documentation for ColdZyme

Related content


Lund 18 October 2017

Complete article from COLDPREV I study published - strengthens documentation for ColdZyme

Enzymatica is presenting the recently published complete article from the COLDPREV I study in the Open Journal of Respiratory Diseases (OJRD). The double-blind placebo-controlled study evaluated ColdZyme

® Mouth Spray

for experimentally induced colds in healthy volunteers.

The study results indicate that ColdZyme significantly reduces viral load and reduces the number of sick days with common cold symptoms.

The study was a pilot study conducted by the Department of Otorhinolaryngology (Ear, Nose and Throat) at Skåne University Hospital, and was previously published as both an abstract and a poster. In this randomised, double-blind placebo-controlled study, 46 subjects were inoculated (infected) with rhinovirus (cold virus). The results show a statistically significant difference between ColdZyme and placebo in reduction of both viral load (quantity of virus) in the throat (-99%) and number of days with common cold symptoms (-54%) from 6.5 to 3 days.

  • The very interesting study results have provided us with valuable information that will aid in the design of future follow-up studies of ColdZyme," says Fredrik Lindberg, CEO of Enzymatica.

ColdZyme Mouth Spray is a CE-marked medical device, with the intended use of reducing the risk of colds or reducing the disease period when early symptoms are present by creating a protective barrier in the mouth and throat.


The analysis and graph are based on the number of people who were confirmed to be infected with the virus, or those who demonstrated symptoms.

Link to the complete article: https://doi.org/10.4236/ojrd.2017.74013

For more information, please contact:

Fredrik Lindberg, CEO, Enzymatica AB

Tel: +46 (0)708-86 53 70 | Email: fredrik.lindberg@enzymatica.com   

About Enzymatica AB

Enzymatica AB is a life science company that develops and sells medical devices for infection-related diseases. The products are based on a barrier technology that includes marine enzymes. The Company's first product is ColdZyme® Mouth Spray, which can prevent colds and reduce the duration of disease. The product has been launched in around ten markets. The strategy is to continue to grow by strengthening the Company's position in existing markets and expanding into new geographic markets through established partners. The company is headquartered in Lund and is listed on Nasdaq First North. For more information please visit: www.enzymatica.se.  

COLDPREV I Eng 171018

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Enzymatica AB via Globenewswire

Attachment: 820844.pdf


Related debate

  • 1 vecka
  • 1 månad
  • 1 År
Ingen indlæg



EuroInvestor: In Focus


EuroInvestor: In Focus


EuroInvestor: In Focus

Mest lästa nyheter

  • 24 timmar
  • 48 timmar
  • 1 vecka
Enzymatica AB: Domstolsutslag lägger restriktioner på Enzymaticas förkylningsspray i Tyskland

Related stock quotes

Enzymatica AB 3,000 -14,3% Aktiepriset minskar

Buy and sell signals

  • Trender
  • Pengamaskinen

Senaste nyheter

Upphovsrätt Euroinvestor A/S 2018  Disclaimer  |  Cookie- og privatlivspolitik  |  Persondatapolitik
Kursinformation levereras av Morningstar.
Alla kurser är fördröjda 15-20 minuter, enligt distributionsavtal fastställda av de olika börserna.
den 16 juli 2018 12:59:57
(UTC+01:00) Brussels, Copenhagen, Madrid, Paris
Version: LiveBranchBuild_20180712.1 - EUROWEB1 - 2018-07-16 12:59:57 - 2018-07-16 12:59:57 - 2 - Website: OKAY